Market Highlights:
Numerous factors are adding to the global acne treatment market growth. These factors, according to the recent Market Research Future report, include a growing teenage population, rising prevalence of acne, increasing health consciousness, and also consciousness about the overall appearance. Additional factors adding to the global acne treatment market growth include increasing intake of high fatty dairy products and high sugar foods, no physical activity, consumption of fatty food, smoking and drinking habits, sedentary habits, rising incidence of hormone imbalance, increase in personal income, and FDA-approvals for acne treatment.
The global acne treatment market Growth is expected to register a CAGR of 5.03% during the forecast period and is expected to hit USD 5383.05 million by 2027.
On the contrary, acute reactions and side effects from non-prescription products and the high price of therapeutic procedures such as dermabrasion, microdermabrasion, and others are factors that may impede the global acne treatment market growth during the forecast period.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/5675
Key Players:
Some of the key players operating in the acne treatment market are GlaxoSmithKline plc, Almirall, SAA, Galderma Laboratories, LP, F. Hoffman La Roche Ltd., Bausch Health Companies Inc., Leo Pharma A/S,Johnson & Johnson Services Inc, Teva Pharmaceutical Industries Ltd., Candela Corporation, and Vyne Therapeutics Inc.
Segment Analysis:
The Market Research Future report provides an all-inclusive segmental analysis of the global acne treatment market based on end users, treatment modality, treatment, and type.
By type, the global acne treatment market is segmented into post-surgical/wound acne, cystic acne, inflammatory acne, comedonal acne, and others. Of these, the inflammatory segment will lead the market during the forecast period.
By treatment, the global acne treatment market is segmented into therapeutic devices, medication, and others. The medication segment is again segmented into antibiotics, retinoid, and others. Retinoid is again segmented into tretinoin, adapalene, and others. Antibiotics are again segmented into clindamycin, erythromycin, and others. Therapeutic devices are again segmented into dermabradors, micro dermabrader lasers, and others. Of these, the medication segment will dominate the market during the forecast period.
By treatment modality, the global acne treatment market is segmented into injectable, topical, and oral.
By end users, the global acne treatment market is segmented into ambulatory surgical centers, pharmacies and drug stores, hospitals and clinics, and others.
Regional Analysis:
The Americas spearheaded the acne treatment market in 2019 and is likely to continue to command during the assessment period. This can be attributed to the high prevalence of acne and skin disorders, product launches, and technological advancement in this region. As per the American Academy of Dermatology Association, nearly 85% of teenagers are affected by acne at some point during their teenage years. In total, over 50 million people have acne in the US. Furthermore, in 2013, the costs associated with acne treatment among those who sought medical care for acne exceeded USD 1.2 billion in the US. This huge contribution of the US in the Americas acne treatment market is anticipated to fuel the regional market growth. Furthermore, regional players are also focused on product development and launch to expand their product portfolio. For instance, in December 2019, Bausch Health Companies Inc., a Canada-based pharmaceutical company announced that the US FDA had approved a new drug application for their tazarotene (ARAZLO), a 0.045% for the topical treatment of acne vulgaris in patients nine years of age and older.
Europe held the second-largest position in the acne treatment market in 2019 owing to the organic growth strategies of companies and a well-developed medical industry in the region. Key players focused on novel product developments and launches are fueling the growth of the acne treatment market in the region. In August 2020, CassiopeaSpA, an Italy-based pharmaceutical company announced that it has cleared the US FDA approval for their Winlevi (clascoterone cream 1%) for the treatment of acne. Similarly, Galderma, a Swiss pharmaceutical company specializing in dermatological treatments and skincare products, has announced its topical retinoid trifarotene 0.005%. The US FDA has approved AKLIEF for the treatment of acne vulgaris. These organic growth strategies help companies to strengthen their position in the European market.
Asia-Pacific is anticipated to register the highest growth rate over the forecast period from 2020 to 2027. This is owing to the high incidence of acne, increased government initiative, and the presence of a large number of pharmaceutical companies. Various initiatives taken by the government to support the healthcare system are also fueling the growth of the regional market. For instance, in August 2020, the government announced the national health ID for every Indian to create a centralized mechanism to identify every participating user in the National Health Stack. Furthermore, increasing disposable income of middle-class families, which accounts for a large population in Asia, encouraging them to spend more on health, is driving the growth of the acne treatment market in the region.
The growth of the acne treatment market in the Middle East & Africa is growing steadily in the past few years. The key factors propelling the market growth are the increasing prevalence of acne and funding by private players and governments. As per the report of the International Trade Administration, The Saudi healthcare sector is the largest in the Near East. Saudi Arabia's health and social affairs budget for 2019 outlines an 8% increase to USD 46 billion as compared to USD 42.4 billion in 2018.
Key Findings of the Study:
- The global acne treatment market was valued at USD 5,383.05 million in 2019 and is expected to register a CAGR of 5.03 % during the forecast period of 2020 to 2027
- The Americas spearheaded the acne treatment market in 2019 and is likely to continue to command during the assessment period. This can be due to the high prevalence of acne and skin disorders, product launch, and technological advancement in this region
- The global acne treatment market, on the basis of acne type, has been segmented into moderate acne, mild acne, moderate to severe acne. Moderate acne is anticipated to be the largest segment accounting for 43.72% in 2019 and fastest-growing market
- Based on treatment, the global acne treatment market is segmented into medication, therapeutic devices. Themedication segment held the largest market share of 86.6%in 2019, whereas the therapeutic devices segment is expected toregistera CAGR of 4.52% during the forecast period of 2020 to 2027
- The global acne treatment market, on the basis of drug type, has been segmented into OTC and prescription. The OTC segment accounted for the largest market share in 2019 owing to high usage of OTC drugs mostly used by the population with mild acne
- The global acne treatment market, on the basis of end user, is segmented into hospitals & clinics and specialty centers. The hospitals & clinics segment accounted for the largest share of 55.42% in 2019
Browse Detailed TOC with COVID-19 Impact Analysis at:
https://www.marketresearchfuture.com/reports/acne-treatment-market-5675
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com